European Agency for Medications (EMA) has approved Veklury (remdesivir) for treatment of Covid-19 in adults and teenagers since the age of 12 - as long as they need additional oxygen supplies. This is mentioned on the website of the agency.
"Remdesivir is the first medicine against COVID-19 to be recommended for authorization in the EU. Data on remdesivir were assessed in an exceptionally short timeframe through a rolling review procedure, an approach used by EMA during public health emergencies to assess data as they become available. From 30 April 2020, the CHMP (human medicines committee, - 112 International) began assessing data on quality and manufacturing, non-clinical data, preliminary clinical data and supporting safety data from compassionate use programs, well in advance of the submission of the marketing authorization application on 5 June", reads the message.
Experts found out that patients who received the drug during the 10-days-long course recovered from Covid-19 in some 11 days, on comparison with 15 days in patients who used to get a placebo. Among the patients who suffered a tough form of the disease, the time of recovery made 12 days in the remdesivir group, and 18 days in the placebo group.
The EMA's human medicines committee also claimed that the drug is given by infusion (drip) into a vein and its use is limited to healthcare facilities in which patients can be monitored closely. The recommended period of treatment spans from four to nine days.